Summary
The prostate cancer Extracellular Vesicle LifeCycle (proEVLifeCycle) network is an innovative, multidisciplinary training
program focused on understanding the biology, biomarker potential and function of extracellular vesicles (EVs) to resolve
unmet clinical needs of prostate cancer (PCa). It is within this realm, that we will equip early stage researchers with the
knowledge, tools and a creative ethos to be independent scientists, leaders, and drivers of innovation. The lifecycle of EVs is
poorly understood and their potential as non-invasive biomarkers and therapy target/agents, a growing area of interest. This
research can perfectly be integrated with the high need for novel biomarkers and therapy targets for PCa. Any relief in the
burden of this disease will have major impact on the huge socio-economic problems for patients, families, caregivers and
society.
The ambitious scientific objectives are to unravel the mysteries of EV biogenesis, homing and uptake to explain how vesicles
operate in disease processes; their heterogeneity, their molecular complexity, the biological functions they drive, their local
and systemic dissemination and how these may be manipulated. Using state-of-the-art, network-wide shared model
systems, imaging and profiling tools, and systems biology, the program will enlighten the lifecycle of EVs and identify novel
EV biomarkers and PCa therapy targets to address the unmet clinical needs.
Our original network of 7 academic and 3 company beneficiaries and 11 partners, provides optimal scientific training, crosssectoral
awareness, entrepreneurship skills, communication in the modern age, extensive opportunities for mobility and
patient-facing experiences. We herein meet identified EU-skills gaps providing well-rounded and inventive experts primed for influential careers, contributing to patient well-being and economic prosperity within the EU.
program focused on understanding the biology, biomarker potential and function of extracellular vesicles (EVs) to resolve
unmet clinical needs of prostate cancer (PCa). It is within this realm, that we will equip early stage researchers with the
knowledge, tools and a creative ethos to be independent scientists, leaders, and drivers of innovation. The lifecycle of EVs is
poorly understood and their potential as non-invasive biomarkers and therapy target/agents, a growing area of interest. This
research can perfectly be integrated with the high need for novel biomarkers and therapy targets for PCa. Any relief in the
burden of this disease will have major impact on the huge socio-economic problems for patients, families, caregivers and
society.
The ambitious scientific objectives are to unravel the mysteries of EV biogenesis, homing and uptake to explain how vesicles
operate in disease processes; their heterogeneity, their molecular complexity, the biological functions they drive, their local
and systemic dissemination and how these may be manipulated. Using state-of-the-art, network-wide shared model
systems, imaging and profiling tools, and systems biology, the program will enlighten the lifecycle of EVs and identify novel
EV biomarkers and PCa therapy targets to address the unmet clinical needs.
Our original network of 7 academic and 3 company beneficiaries and 11 partners, provides optimal scientific training, crosssectoral
awareness, entrepreneurship skills, communication in the modern age, extensive opportunities for mobility and
patient-facing experiences. We herein meet identified EU-skills gaps providing well-rounded and inventive experts primed for influential careers, contributing to patient well-being and economic prosperity within the EU.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/860303 |
| Start date: | 01-10-2019 |
| End date: | 30-09-2023 |
| Total budget - Public funding: | 2 672 561,88 Euro - 2 672 561,00 Euro |
Cordis data
Original description
The prostate cancer Extracellular Vesicle LifeCycle (proEVLifeCycle) network is an innovative, multidisciplinary trainingprogram focused on understanding the biology, biomarker potential and function of extracellular vesicles (EVs) to resolve
unmet clinical needs of prostate cancer (PCa). It is within this realm, that we will equip early stage researchers with the
knowledge, tools and a creative ethos to be independent scientists, leaders, and drivers of innovation. The lifecycle of EVs is
poorly understood and their potential as non-invasive biomarkers and therapy target/agents, a growing area of interest. This
research can perfectly be integrated with the high need for novel biomarkers and therapy targets for PCa. Any relief in the
burden of this disease will have major impact on the huge socio-economic problems for patients, families, caregivers and
society.
The ambitious scientific objectives are to unravel the mysteries of EV biogenesis, homing and uptake to explain how vesicles
operate in disease processes; their heterogeneity, their molecular complexity, the biological functions they drive, their local
and systemic dissemination and how these may be manipulated. Using state-of-the-art, network-wide shared model
systems, imaging and profiling tools, and systems biology, the program will enlighten the lifecycle of EVs and identify novel
EV biomarkers and PCa therapy targets to address the unmet clinical needs.
Our original network of 7 academic and 3 company beneficiaries and 11 partners, provides optimal scientific training, crosssectoral
awareness, entrepreneurship skills, communication in the modern age, extensive opportunities for mobility and
patient-facing experiences. We herein meet identified EU-skills gaps providing well-rounded and inventive experts primed for influential careers, contributing to patient well-being and economic prosperity within the EU.
Status
CLOSEDCall topic
MSCA-ITN-2019Update Date
28-04-2024
Images
No images available.
Geographical location(s)
Structured mapping
Search
Organisations
-
| ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (Coördinator)
-
| AIT AUSTRIAN INSTITUTE OF TECHNOLOGY GMBH (AIT Austrian Institute of Technology GmbH)
-
| ANAXOMICS BIOTECH SL
-
| ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS
-
| CARDIFF UNIVERSITY
-
| FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III
-
| GenomeScan B.V.
-
| INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
-
| TURUN YLIOPISTO (UTU)
-
| UNIVERSITAIR MEDISCH CENTRUM UTRECHT